Clinical Trials
3
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
CT-322 in Combination With Radiation Therapy and Temozolomide to Treat Newly Diagnosed Glioblastoma Multiforme
- Conditions
- Glioblastoma Multiforme
- Interventions
- First Posted Date
- 2008-10-08
- Last Posted Date
- 2010-10-27
- Lead Sponsor
- Adnexus, A Bristol-Myers Squibb R&D Company
- Target Recruit Count
- 30
- Registration Number
- NCT00768911
- Locations
- 🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
🇺🇸University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸University of Kentucky Hospital, Lexington, Kentucky, United States
CT-322 in Treating Patients With Recurrent Glioblastoma Multiforme and Combination Therapy With Irinotecan
- Conditions
- Brain and Central Nervous System TumorsRecurrent Glioblastoma Multiforme
- Interventions
- First Posted Date
- 2007-11-22
- Last Posted Date
- 2010-10-27
- Lead Sponsor
- Adnexus, A Bristol-Myers Squibb R&D Company
- Target Recruit Count
- 72
- Registration Number
- NCT00562419
- Locations
- 🇺🇸
University of California, San Diego, La Jolla, California, United States
🇺🇸University of Kentucky, Lexington, Kentucky, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
CT-322 in Treating Patients With Advanced Solid Tumors and Non-Hodgkin's Lymphoma
- Conditions
- Cancer
- First Posted Date
- 2006-09-11
- Last Posted Date
- 2009-02-24
- Lead Sponsor
- Adnexus, A Bristol-Myers Squibb R&D Company
- Target Recruit Count
- 40
- Registration Number
- NCT00374179
- Locations
- 🇺🇸
Indiana University Cancer Center, Indianapolis, Indiana, United States
🇺🇸South Texas Accelerated Research Therapeutics, San Antonio, Texas, United States
🇺🇸Institute for Drug Development, San Antonio, Texas, United States